# Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B

> **NCT02618915** · PHASE1,PHASE2 · TERMINATED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 6 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** DTX101

## Key facts

- **NCT ID:** NCT02618915
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-16
- **Primary completion:** 2017-10-18
- **Final completion:** 2017-10-18
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor decision; not due to any safety concerns related to DTX101.
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02618915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02618915, "Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02618915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*